STAT x Harvard Medical School: Confronting a pandemic

To access today's chat, please visit: https://bostonglobe.zoom.us/j/92662895400

ABOUT:

The need to respond to the coronavirus pandemic is forcing technology-enabled change in health care at an unprecedented speed. Barriers that have existed for years — whether regulatory, logistical, or scientific — are falling. Join STAT for a four-part digital event series jointly developed and delivered by Harvard Medical School to discuss everything from the rapid deployment of telehealth to the development of drugs and vaccines.

This series will take place on Zoom, and attendees will be able to both see the discussions live, and participate by asking questions as well. Access to the event is free. Access to the Zoom platform is limited to the first 1,000 attendees; any additional attendees will be able to watch the conversation in real-time via a live stream on STAT’s website.

SCHEDULE:

Please note, dates and times are subject to change as the story evolves.

Part 1: New biopharma collaborative models for Covid-19

On May 7, we hosted the first session of this series. STAT San Francisco correspondent Rebecca Robbins, and Stanley Shaw, M.D., Ph.D., associate dean for executive education at Harvard Medical School, were joined by Jay Bradner, M.D., president of Novartis Institutes for BioMedical Research (NIBR), and Andrew Plump, M.D., Ph.D., president of research & development at Takeda Pharmaceutical. The topic: How biopharma companies are being pushed to develop treatments more rapidly than ever before — and, with that, to evolve how they collaborate at every stage of the drug development pipeline. Watch the full recording of this session here.

Part 2: Telemedicine during the Covid-19 pandemic - the new normal?

On May 12, we hosted part two of this series. STAT health tech correspondent correspondent Erin Brodwin, and Stanley Shaw, M.D., Ph.D., associate dean for executive education at Harvard Medical School, were joined by John Glaser Ph.D., president, American Telemedicine Association; former, senior vice-president, population health, Cerner; former CEO, Siemens Health Services, and Lee Schwamm, M.D., vice president of virtual care, Partners Healthcare Digital Health; director, MGH Center for TeleHealth; executive vice chairman, Department of Neurology, MGH. This time, they discussed how virtual visits and telemedicine operations are impacting care now and what the post-Covid-19 landscape might look like. Watch the full recording of this session here.

Part 3: Tech solutions for Covid-19 surveillance and contact tracing

On May 21, we hosted part 3 of this series. STAT national technology correspondent Casey Ross and Stanley Y. Shaw, M.D., Ph.D., associate dean for executive education at Harvard Medical School, were joined by John Brownstein, Ph.D., chief innovation officer at Boston Children's Hospital, professor of pediatrics at Harvard Medical School and Dena Mendelsohn, J.D., M.P.H., director of health policy and data governance at Elektra Labs. This time, they discussed how technology companies are being deployed in surveillance and contact tracing efforts to control the spread of Covid-19. Watch the full recording of this session here.

Part 4: The foundations of reopening

May 28 at 1 p.m. EST

Speakers:

• Gilad S. Gordon, M.D., M.B.A, president, ORRA Group, LLC and associate clinical professor of medicine, University of Colorado School of Medicine
• Joia Mukherjee, M.D., M.P.H., chief medical officer, Partners in Health; associate professor, Harvard Medical School

Moderators:

• Helen Branswell, senior writer, infectious disease, STAT
• Stanley Y. Shaw, M.D., Ph.D., associate dean for executive education, Harvard Medical School

JOINTLY DEVELOPED AND DELIVERED BY HARVARD MEDICAL SCHOOL

ABOUT HARVARD MEDICAL SCHOOL EXECUTIVE EDUCATION

Harvard Medical School Executive Education engages business leaders whose work impacts health care and exposes them to the real-world practice of medicine, cutting-edge trends in science, clinical workflows and health care delivery.